Growth hormone is one of those molecules where the details matter more than the headlines. The simple version — "more GH is better" — misses something fundamental about how your body actually uses growth hormone. Your pituitary does not secrete GH in a constant stream. It releases GH in pulses — sharp bursts followed by periods of near-zero levels — and this pulsatile pattern is not a design flaw. It is the design.
Understanding this distinction between pulsatile and sustained GH elevation is the key to understanding why CJC-1295 without DAC (also called Modified GRF 1-29 or mod-GRF) has become one of the most studied growth hormone-releasing hormone analogues in the research community. It is also the key to understanding why the "without DAC" part of the name matters so much.
CJC-1295 without DAC is a modified version of the first 29 amino acids of natural GHRH that produces pulsatile GH release lasting approximately 30 minutes per pulse, mimicking the body's natural pattern. The DAC version produces sustained GH elevation lasting 8-10 days — a fundamentally different pharmacological profile. Pulsatile release preserves negative feedback sensitivity and reduces the risk of receptor desensitization, and combining CJC-1295 no-DAC with Ipamorelin produces synergistic GH release 2-10 times greater than either alone. This GHRH plus GHRP combination is one of the most studied peptide protocols in growth hormone research.
The physiology of GH pulsatility
To appreciate what CJC-1295 no-DAC does, you need to understand how GH secretion works naturally. Your hypothalamus produces two opposing signals: GHRH (growth hormone-releasing hormone), which tells the pituitary to secrete GH, and somatostatin, which tells it to stop.
These signals alternate in a rhythmic pattern. GHRH dominates for a period, triggering a GH pulse. Then somatostatin takes over, shutting down secretion and allowing GH levels to drop near zero. Then the cycle repeats. In young adults, this produces roughly 6-12 GH pulses per 24 hours, with the largest pulse occurring during the first phase of deep sleep.
This pulsatile pattern is essential, not incidental. Research published in the Journal of Clinical Investigation demonstrated that the same total amount of GH, delivered in a pulsatile pattern versus a continuous infusion, produces markedly different biological effects. Pulsatile delivery preferentially activates certain signaling pathways (particularly the JAK2/STAT5 pathway responsible for IGF-1 production and tissue growth), while continuous delivery leads to receptor downregulation and diminished response over time.
The body evolved this system for a reason. The periods between pulses — when GH is near zero — allow GH receptors to resensitize, ensuring that each subsequent pulse produces a full biological response. Eliminate the troughs, and you gradually lose sensitivity to the peaks.
For my own research protocols, I source CJC-1295 through Solira Peptides — third-party tested, pharmaceutical-grade purity on every batch.
What CJC-1295 no-DAC actually is
CJC-1295 without DAC is a synthetic analogue of GHRH — specifically, a modified version of the first 29 amino acids of native GHRH (which is 44 amino acids long). The first 29 amino acids contain the full receptor-binding and biological activity of the full-length molecule — the remaining 15 amino acids are not required for function.
The modifications are at four positions in the amino acid chain (positions 2, 8, 15, and 27), where natural amino acids have been replaced with substitutes that resist enzymatic degradation. Native GHRH(1-29) — also known as Sermorelin — has a half-life of roughly 10-20 minutes in vivo because serum proteases chew it up rapidly. The modifications in CJC-1295 no-DAC extend the half-life to approximately 30 minutes, which is long enough to produce a meaningful GH pulse but short enough to preserve the pulsatile pattern.
This is the critical distinction. A 30-minute half-life means that after administration, CJC-1295 no-DAC stimulates a GH pulse, then clears the system, allowing GH to return to baseline. The pituitary has time to recover. Somatostatin has time to reassert control. GH receptors have time to resensitize. The natural rhythm is preserved.
The DAC version: a different philosophy
CJC-1295 with DAC (Drug Affinity Complex) includes a maleimidopropionic acid linker that binds to serum albumin after injection. This extends the half-life from 30 minutes to approximately 8-10 days. The result is sustained GH elevation over more than a week from a single injection.
The original paper by Teichman and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 2006, showed that a single subcutaneous injection of CJC-1295 with DAC produced sustained elevation of GH and IGF-1 levels for 6-14 days. Mean GH levels increased 2-10 fold, and IGF-1 levels increased 1.5-3 fold above baseline.
That sounds impressive on paper, and the convenience of infrequent dosing is obvious. But here is the concern that drives many researchers toward the no-DAC version: sustained GH elevation is not how the body works. It eliminates the troughs between pulses, maintains continuous stimulation of the GH receptor, and bypasses the somatostatin-mediated feedback that normally regulates the system.
The theoretical risks of sustained elevation include receptor desensitization over time, potential for somatotroph cell exhaustion in the pituitary, blunting of the natural diurnal GH rhythm, and the possibility that continuous GH receptor activation produces different downstream effects than pulsatile activation.
I want to be balanced here: CJC-1295 with DAC has been studied in clinical trials and the short-term data did not show dramatic adverse effects. But the long-term implications of overriding the body's pulsatile pattern are not fully characterized, and many researchers prefer the no-DAC version specifically because it works with the body's natural rhythm rather than against it.
There is also a practical consideration around side effects. Sustained GH elevation from the DAC version means that any side effects — water retention, joint stiffness, carpal tunnel-like symptoms, or insulin sensitivity changes — persist for the full 8-10 day duration. With the no-DAC version, GH elevation is transient and self-limiting, so any acute side effects resolve within hours. If an individual responds poorly to GH elevation, the no-DAC version provides a natural off-switch that the DAC version does not.
The age-related GH decline
One of the reasons GH secretagogues have attracted so much research attention is the well-documented decline in GH output with aging — sometimes called somatopause. GH secretion peaks during puberty, begins declining in the third decade of life, and continues to fall at approximately 14% per decade thereafter. By age 60, many adults produce less than half the GH they did at 25.
This decline is not primarily due to pituitary failure. The somatotroph cells remain capable of releasing GH when properly stimulated. The problem appears to be upstream — a shift in the balance between GHRH and somatostatin signaling from the hypothalamus, with somatostatin tone increasing relative to GHRH drive. This matters because it means the pituitary can still respond to exogenous GHRH stimulation. CJC-1295 no-DAC works precisely because the downstream machinery is intact — it provides the GHRH signal that the aging hypothalamus delivers less effectively.
This is why GHRH analogues are often preferred over direct GH injection in the longevity research context. They work with the existing system, producing GH release that is constrained by the pituitary's own regulatory mechanisms, rather than introducing an external hormone that bypasses all controls.
Stacking with Ipamorelin: the GHRH plus GHRP synergy
This is where the pharmacology gets really elegant. CJC-1295 no-DAC is a GHRH analogue — it works by stimulating the GHRH receptor on pituitary somatotrophs. Ipamorelin is a growth hormone-releasing peptide (GHRP) — it works by activating the ghrelin receptor (GHS-R1a) on those same somatotrophs.
These are two completely different receptor systems that converge on the same outcome: GH release. And when you activate both simultaneously, the effect is not additive — it is synergistic. The combined GH output is typically 2-10 times greater than either compound alone.
A study published in the Journal of Clinical Endocrinology and Metabolism demonstrated this synergy directly: co-administration of GHRH and a GHRP produced GH peaks that were dramatically higher than the sum of the individual responses. The mechanism appears to involve intracellular signaling crosstalk — the GHRH receptor and the ghrelin receptor use partially overlapping but distinct second messenger pathways, and simultaneous activation produces a multiplicative effect on the exocytotic release of stored GH vesicles.
Ipamorelin is the preferred GHRP for this pairing because of its selectivity. Unlike older GHRPs (GHRP-6, GHRP-2, hexarelin), Ipamorelin produces virtually no increase in cortisol, prolactin, or appetite. It does the one thing you want — stimulate GH release — without the off-target effects that complicate other GHRP options.
The CJC-1295 no-DAC plus Ipamorelin combination has become something of a reference standard in growth hormone peptide research. It produces robust GH pulses, preserves pulsatility, avoids off-target hormonal effects, and the synergistic mechanism means lower doses of each component can achieve meaningful GH output.
Research formulations for CJC-1295 no-DAC are typically studied at concentrations of 5mg (ref: CND5) and 10mg (ref: CND10).
How it compares to other GHRH options
Sermorelin
Sermorelin is the unmodified GHRH(1-29) fragment — the same first 29 amino acids without the four substitutions that CJC-1295 no-DAC has. It works through the same receptor and produces the same type of pulsatile GH release. The difference is purely pharmacokinetic: Sermorelin's half-life is roughly 10-20 minutes versus 30 minutes for CJC-1295 no-DAC.
In practical terms, this means Sermorelin produces a shorter, potentially smaller GH pulse. It still preserves the natural pattern, but the amplitude and duration of each pulse are somewhat less. Sermorelin has the advantage of a longer track record — it was FDA-approved for diagnostic use and has been used clinically for decades — but the pharmacokinetic profile of CJC-1295 no-DAC is generally considered superior for research purposes.
Tesamorelin
Tesamorelin is a GHRH analogue with a trans-3-hexenoic acid modification that enhances potency and half-life. It is FDA-approved for the reduction of excess abdominal fat in HIV-associated lipodystrophy — making it one of the few GHRH analogues with an approved clinical indication and substantial human safety data.
Tesamorelin produces pulsatile GH release similar to CJC-1295 no-DAC but with a longer half-life of approximately 26 minutes (still within the pulsatile range). The clinical trial data for Tesamorelin is the most robust of any GHRH analogue, with documented reductions in visceral adipose tissue, improved body composition, and acceptable safety profiles in multi-year studies.
CJC-1295 with DAC
As discussed above, the DAC version represents a fundamentally different approach — sustained elevation versus pulsatile release. It is more convenient (less frequent dosing) but departs from the physiological pattern. The choice between them often reflects the researcher's philosophy: do you prioritize convenience and total GH output, or do you prioritize preserving the body's natural secretory rhythm?
Timing and administration research
The research literature on CJC-1295 no-DAC administration timing generally reflects an understanding of the body's natural GH rhythm. The largest natural GH pulse occurs during the first phase of deep sleep (typically within the first 1-2 hours of falling asleep), driven by a natural GHRH surge from the hypothalamus.
Research protocols frequently time administration to coincide with or precede this natural pulse, reasoning that the exogenous GHRH signal will amplify the endogenous one. Evening administration, approximately 30-60 minutes before sleep, allows the peptide-stimulated GH pulse to merge with the natural sleep-associated pulse, potentially producing a larger combined peak.
Some research protocols also include a morning or mid-afternoon dose to add an additional GH pulse during waking hours. Natural GH pulses occur throughout the day (not just at night), and adding exogenous pulses during the daytime can increase total GH exposure while still preserving the pulsatile pattern — as long as the half-life is short enough to allow return to baseline between doses.
Who benefits from which approach
For anti-aging and longevity-focused research, pulsatile release is generally preferred because it mimics the youthful GH secretory pattern that declines with age. The goal is not to create supraphysiological GH levels but to restore the amplitude and frequency of pulses to levels seen in younger individuals. CJC-1295 no-DAC, especially combined with Ipamorelin, is well-suited for this approach.
For body composition research focused on maximizing fat loss and lean mass gain, some researchers prefer the sustained elevation of the DAC version or direct GH administration, reasoning that total GH exposure over time is the primary driver. The pulsatile approach may achieve comparable body composition outcomes with a lower total GH dose, though, thanks to preserved receptor sensitivity.
For recovery-focused research, the pulsatile approach again has the edge, as GH's tissue repair effects appear to be most effectively triggered by peak concentrations during pulses rather than by continuous low-level elevation. The deep sleep GH pulse, in particular, is associated with tissue repair and recovery processes.
Frequently asked questions
What does "without DAC" actually mean?
DAC stands for Drug Affinity Complex — a chemical modification (maleimidopropionic acid) that binds to serum albumin after injection, extending the half-life from about 30 minutes to 8-10 days. "Without DAC" means the peptide lacks this modification and clears the body relatively quickly, producing a discrete GH pulse rather than sustained elevation. The two versions share the same core GHRH analogue structure but have fundamentally different pharmacokinetic profiles.
Why is pulsatile GH release considered better than sustained?
Your body naturally releases GH in pulses, not as a continuous stream. The periods between pulses allow GH receptors to resensitize, ensuring each pulse produces a full response. Research shows that the same total amount of GH delivered in pulses versus continuously produces different biological effects — pulsatile delivery better activates growth-related signaling pathways (JAK2/STAT5) and avoids the receptor desensitization that can occur with continuous stimulation.
How does the CJC-1295 and Ipamorelin combination produce synergy?
CJC-1295 no-DAC activates the GHRH receptor and Ipamorelin activates the ghrelin receptor (GHS-R1a). These are two distinct receptor systems on pituitary somatotroph cells. When activated simultaneously, their intracellular signaling pathways interact multiplicatively rather than additively, producing GH release 2-10 times greater than either alone. This synergy is well-documented in the endocrinology literature and is the primary reason the combination has become a standard research protocol.
Does CJC-1295 no-DAC increase IGF-1 levels?
Yes. GH stimulates the liver to produce IGF-1, which mediates many of GH's growth and repair effects. Research shows that CJC-1295 no-DAC administration, particularly in combination with a GHRP, produces measurable increases in IGF-1 levels. The pulsatile pattern is effective at driving IGF-1 production because the liver responds robustly to GH peaks. The IGF-1 elevation is typically more moderate than what is seen with exogenous GH injection, reflecting the fact that GHRH analogues work within the body's regulatory constraints.
How does CJC-1295 no-DAC compare to direct GH injection?
Direct GH injection provides exogenous GH — you are introducing the hormone itself from an external source. CJC-1295 no-DAC stimulates your own pituitary to produce and release GH endogenously. The advantages of the GHRH approach include preserved negative feedback, pulsatile release pattern, stimulation of the full spectrum of GH isoforms (the pituitary releases multiple GH variants, not just the 22kDa form in pharmaceutical GH), and avoidance of supraphysiological peaks. The disadvantage is that efficacy depends on a functioning pituitary — if it is significantly impaired, GHRH analogues will produce a diminished response.